Biomarkers for the early-detection and monitoring of Huntington’s disease 7th World CNS Summit: Targeting Neurodegenerative Diseases, Boston, MA (2019) Salzman DW, Bregu J, Ray NS, Myers RH
Biomarkers for the early-detection and monitoring of Huntington’s Disease RNA-Based Biomarker Grant (completion 2021) Salzman DW, Bregu J, Ray NS, Myers RH
An AI-driven platform to classify and subtype CNS disease using small RNAs Neuroimaging and CSF Biomarker Development Grant (completion 2021) Salzman DW, Melconian T, Foster N, Ray NS
Thanks for your interest! Please fill out the form below to download a copy of our case study
David Salzman, PhD
As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.
If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.